A new, reliable and effective RA drug can be developed by blocking a link in the pyroptosis activation pathway from the perspective of CD4+ T cell death form, prolonging T cell lifespan and avoiding T cell-mediated inflammatory responses. Here, CD4 is linked to rheumatoid arthritis.